Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Aspen vs Breeze Meds

Aspen
Graded #372

Lower grade

vs+14.000000000000007
Breeze Meds
Graded #55

Higher grade

The verdict

Breeze Meds takes it — 72.4/100 to 58.4/100.

Breeze Meds grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Charges nothing until a provider approves you — but keeps its pricing inside the intake.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueBreeze Meds +45
27
72
Dose & formulationBreeze Meds +2
64
66
Clinical oversightAspen +4
80
76
Labs & monitoringBreeze Meds +8
52
60
FulfillmentAspen +10
94
84
Contract termsBreeze Meds +39
47
86
Aspen · left barBreeze Meds · right bar

The numbers

MetricAspenBreeze Meds
WeighScore58.4/10072.4/100
GradeCC
Scorecard rank#372#55
Semaglutide$279/mo (3-month plan, compounded)From $199/mo
Tirzepatide$399/mo (compounded)From $299/mo first month, $399/mo thereafter
CoverageAll 50 statesAll 50 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
Aspen

Graded #372 · C

Strengths

  • LegitScript-certified with an independently verifiable seal (#50306023) and HIPAA compliance — a strong trust signal for a compounded-GLP-1 telehealth
  • Names its dispensing pharmacy: Red Rock Compounding Pharmacy, LegitScript-certified and NABP-accredited, licensed in 49 states plus DC
  • Flat pricing at every dose ("same price at every dose, no surprises") plus free expedited shipping, so your cost won't rise as you titrate up
  • Competitive prepay rates — compounded semaglutide as low as $179/mo (12-mo) and tirzepatide $299/mo — with zero interest and no credit check
  • Money-back guarantee for qualifying patients who complete the full 28-week program without losing weight; available in all 50 states + DC

Where it loses points

  • Compounded semaglutide and tirzepatide only — no brand-name Wegovy, Zepbound or Ozempic — and compounded GLP-1s aren't FDA-reviewed or approved
  • Even the "monthly" plan requires a 3-month commitment with three months of medication shipped and billed upfront — limited month-to-month flexibility
  • Standing month-to-month pricing is steep ($279 semaglutide, $399 tirzepatide); the lowest rates require 6- or 12-month prepay
  • The provider chooses semaglutide vs tirzepatide for you, so you can't freely pick your own molecule
  • Registered as Aspen Health Systems LLC at a Sheridan, WY address; async model with no routine video visit
Breeze Meds

Graded #55 · C

Strengths

  • Nothing charged until a provider approves you, and the consult is free if you go ahead
  • One inclusive price covering consult, medication, supplies, shipping and support
  • LegitScript certified, all 50 states, cancel or change plan at any time
  • NAD+ injections offered alongside the GLP-1 line

Where it loses points

  • The public site names no molecule behind its "from $199" — tirzepatide pricing appears only inside the intake
  • Every quoted figure is for the LOWEST dose; the funnel says higher doses may cost more
  • An $80 consultation fee applies if you are approved and then decline
  • Injection only, compounded only, with no published lab programme

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard